THP

DRUG2 trials

Sponsors

Fudan University, Shanghai Henlius Biotech

Conditions

HER2 + Breast CancerHER2-positive Breast Cancer

Phase 2

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

Not yet recruitingNCT06548178

Fudan UniversityHER2-positive Breast Cancer

Start: 2024-09-30End: 2028-09-30Target: 242Updated: 2024-08-12

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

RecruitingNCT07294508

Shanghai Henlius BiotechHER2 + Breast Cancer

Start: 2026-02-27End: 2030-12-30Target: 706Updated: 2026-03-20